Single-center, Open-label, Phase 1 Study Consisting of a Single-dose Pilot Phase and a Randomized, Two-way Crossover, Single-dose Main Phase to Investigate the Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Male Subjects
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Selexipag (Primary) ; Selexipag (Primary)
- Indications Arteriosclerosis obliterans; Pulmonary arterial hypertension; Pulmonary hypertension; Raynaud's disease
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 24 Nov 2016 Results assessing bioavailability of oral (tablet) versus intravenous (i.v.) formulation of selexipag in healthy subjects published in the European Journal of Clinical Pharmacology.
- 12 Sep 2016 New trial record